Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

The concern of endophthalmitis is casting a larger spector over the treatment of ocular conditions with intravitreal injection. Bevacizumab is typically obtained through such compounding ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal faricimab injections, and occlusive retinal vasculitis d ...

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

This systematic review and meta-analysis aimed to comprehensively describe the efficacy and safety of intravitreal anti-VEGF injection with bevacizumab, ranibizumab, aflibercept, or pegaptanib and ...

The BEVacizumab OR DEXamethasone for diabetic macular oedema ... In summary, this study suggests that there is a reduction in the retinal venular calibre following intravitreal injections of DEX not ...

Administration of bevacizumab or ranibizumab costs £61 ($96; SD: £14) per injection, while each consultation for monitoring costs £72 ($113; SD: £41), plus £39 ($61; SD: £16) for each FFA.

Intravitreal injection of anti-VEGF drugs such as ranibizumab (Lucentis ... of whom 2639 received anti-VEGF for reasons other than nAMD or received bevacizumab. Thus, this study analyses data on 12 ...

A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...